How do you pay?

How to pay the least

Lowest posted price

from $20 a prescription

Gimoti from Evoke Pharma, without insurance.

  1. Sign up for GIMOTI Copay Program (ASPN Pharmacies). Or call 1-844-244-6684.Sign up on gimotirx.com 

We didn’t find one.

Compare every option

Question
Brand nameGimoti
Authorized genericmetoclopramide
Regular genericmetoclopramide
What you’d pay
From$20a prescription with the maker’s card
Not soldThere isn’t one
Not soldNone found
Same as Gimoti?
The original
–
–

Brand nameThe maker’s card

GIMOTI Copay Program (ASPN Pharmacies)

Savings card from Evoke Pharma

No insurance · from $20 a prescription
Insurance $0 a prescription

Sign up on gimotirx.com 

Or call 1-844-244-6684.

In the maker’s words

“$0 or $20 copay for eligible patients…”

From the maker’s offer on gimotirx.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s price above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Gimoti itself, from the same company, sold without the brand name, and usually for less. For now Gimoti is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

GIMOTI is a dopamine-2 (D 2) antagonist indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.

Limitations of Use:

GIMOTI is not recommended for use in:

  • pediatric patients due to the risk of tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates.
  • moderate or severe hepatic impairment (Child-Pugh B or C), moderate or severe renal impairment (creatinine clearance less than 60 mL/minute), and patients concurrently using strong CYP2D6 inhibitors due to the risk of increased drug exposure and adverse reactions.

Source: the FDA label for Gimoti (Evoke Pharma, Inc.), February 20, 2026. Full label on DailyMed 

Good to know